Trials / Terminated
TerminatedNCT06210243
C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma
A Single-arm, Open-label Clinical Study to Assess the Safety and Efficacy of the C752 CAR-T Cells for Patients With CD19+ Refractory/Relapsed B Cell Non-Hodgkin Lymphoma
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
It is a single-arm, open-label clinical study to assess the safety and efficacy of the C752 CAR-T Cells for patients with CD19+ refractory/relapsed B cell non-Hodgkin lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | C752 | C752 will be administered on Day 0 |
Timeline
- Start date
- 2023-12-24
- Primary completion
- 2024-12-24
- Completion
- 2024-12-24
- First posted
- 2024-01-18
- Last updated
- 2025-02-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06210243. Inclusion in this directory is not an endorsement.